$16.95 -0.10 (-0.59%)
11/20/2009 4:00 PM

Cubist Pharmaceuticals, Inc. (CBST)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

Current Price $16.95 Mkt Cap $982.2M
Open $17.03 P/E Ratio 5.01
Prev. Close $17.05 Div. (Yield) N/A (N/A)
Daily Range $16.85 - $17.22 Volume 1,044,573
52-Wk Range $13.81 - $28.74 Avg. Daily Vol. 979,000

CBST News and Commentary

Caps

How do you think CBST will perform vs the S&P 500?

Add Stock to Watchlist

All Members

250 Outperform
16 Underperform
 

All-Star Members

64 Outperform
6 Underperform
 

Wall Street

10 Outperform
2 Underperform
 

Top CBST Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

BetapegLLC (88.76)
Submitted November 17, 2009

Cubist’s spectacular growth is highlighted by its 517% revenue increase from 2004 and 253% profit increase from 2007. Their primary marketable product (CUBICIN) has proven to be a success. The Company is active with seven new drugs in the “pipeline”… More

narlinbeaty (56.29)
Submitted May 17, 2008

This company make a drung called Daptomyocin. The drug is affective against MRSA and is used internationally for skin infections and bactermia. In many ways ths drug is a heavy hitting antiboitic used has last line of defense in the hospital setting.… More

CBST VS S&P 500 (SPY)

Fools bullish on CBST are also bullish on:

Recent Community Commentary

Read the most recent pitches from members about CBST.

Recs

2
Member Avatar BetapegLLC (88.76) Submitted: 11/17/2009 11:30:46 AM : Outperform Start Price: $17.36 CBST Score: -4.60

Cubist’s spectacular growth is highlighted by its 517% revenue increase from 2004 and 253% profit increase from 2007. Their primary marketable product (CUBICIN) has proven to be a success. The Company is active with seven new drugs in the “pipeline” with the goal of final FDA approval. This could prove lucrative for stock holders. Earnings yield, return on equity, and profit margin are all well above average. The Company’s excellent cash position enables it to pay off all its creditors today or within two years on profit alone. The PE, PB, and PS ratios are all below the sector average indicating the stock to be substantially undervalued. The Company has outperformed 25% of the market in the last 12 months indicating the stock to be substantially undervalued relative to its fundamentals grade of 90%. Cubist is valued at $37.32 and is substantially undervalued at a current price of $17.34 (November 13, 2009). The technicals indicate a bullish rectangle pattern. The stock can be expected to remain flat or go higher short term. Well known institutionals such as Vanguard, Barclays, and T. Rowe Price have large stakes in Cubist. Risks include reliance on one flagship product, possible failure to obtain FDA approval, competition including patent infringement, litigation, dependence on third parties to manufacture products, etc. For more risks, see section 1A of the 2008 Annual Report.

http://betapeg.com/stock_picks__reports

Recs

0
Member Avatar toolboy2 (98.02) Submitted: 11/4/2009 9:10:26 PM : Outperform Start Price: $16.93 CBST Score: -3.31

Initiated coverage on these guys last month. They develop drugs in the acute care environment, such as skin and blood infections. Excellent fundamentals: low P/E and PEG ratios, very healthy profit margins and ROE north of 60%. Only drawback for me is their debt load (D/E=0.55), but that's to be expected in the biopharmaceutical industry. With nearly $500 million cash, their balance sheet is in overall good shape.

wallstreetbean.com

Recs

0
Member Avatar smith972 (83.43) Submitted: 11/4/2009 6:19:39 PM : Outperform Start Price: $16.75 CBST Score: -2.37

Cubist maybe a takeover target.

Leaderboard

Find the members with the highest scoring picks in CBST.

Score Leader

GrandmasterC00

GrandmasterC00 (< 20) Score: +67.40

The Score Leader is the member with the highest score across all their picks in CBST.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
hwyman64 97.48 11/12/2008 Underperform 3W $24.25 -30.10% +29.58% +59.68
lwc123 88.50 1/8/2009 Underperform 3Y $24.82 -31.71% +23.52% +55.23
BLOWKE < 20 10/16/2008 Underperform 3W $19.50 -13.07% +25.05% +38.11
riskybus < 20 3/2/2009 Underperform NS $14.11 +20.13% +53.57% +33.44
jeffbenes < 20 2/1/2008 Outperform NS $17.09 -0.82% -17.32% +16.50
RICKDBELL 77.42 2/1/2008 Outperform 5Y $17.09 -0.82% -17.32% +16.50
VanGundy1 31.95 1/19/2007 Outperform 5Y $17.70 -4.24% -18.72% +14.48 1 Comment
germbuster 32.74 3/24/2008 Outperform NS $17.20 -1.45% -14.87% +13.42
Oneofeach 31.00 6/17/2008 Outperform 3Y $17.68 -4.13% -16.50% +12.37
UtahHick 28.99 2/4/2008 Outperform 1Y $18.04 -6.04% -18.08% +12.03

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackOppenheimer < 20 8/6/2009 Underperform NS $20.57 -15.80% +4.33% +20.13 10/29/2009 @ $17.32
TrackWedbush < 20 3/20/2009 Outperform NS $15.70 +7.96% +42.61% -34.65
TrackThinkEquity 43.24 2/20/2009 Outperform NS $17.00 -0.29% +45.19% -45.48
TrackLeerinkSwan 83.04 12/8/2008 Underperform NS $25.88 -34.51% +24.19% +58.70
TrackRodmanRen < 20 11/20/2008 Outperform NS $22.19 -23.61% +40.11% -63.73
TrackMerriman < 20 10/30/2008 Outperform NS $22.75 -25.49% +16.87% -42.36
TrackJimCramer 36.31 10/29/2008 Outperform 3W $22.35 -24.16% +20.61% -44.77
TrackNeedham < 20 7/1/2008 Outperform NS $18.01 -5.89% -10.81% +4.93
TrackStanfordRes 78.48 1/24/2008 Outperform NS $19.07 -11.12% -14.77% +3.66
TrackRWBaird 81.68 1/15/2008 Outperform NS $21.50 -12.84% -24.78% +11.94 10/7/2009 @ $18.74
TrackStifel 93.96 7/19/2007 Outperform NS $22.85 -25.82% -25.78% -0.04
TrackLazardCapit < 20 4/19/2007 Underperform NS $20.79 +9.91% +5.84% -4.07 7/19/2007 @ $22.85
TrackJMP < 20 1/5/2007 Outperform NS $17.07 -0.70% -17.82% +17.11
TrackJefferies 31.78 10/16/2006 Outperform NS $22.62 -25.07% -14.92% -10.15
TrackMatrix 87.46 8/31/2006 Underperform NS $23.52 -27.93% -10.84% +17.09

Featured Broker Partners